Prescribing Safety Assessment (PSA) Practice Exam

Which substance is used as part of the management protocol for NSTEMI that also serves as a recommended anticoagulant?

1. Fondaparinux

2. Warfarin

3. Rivaroxaban

4. Enoxaparin

The correct answer is: Fondaparinux

Fondaparinux is indeed a recommended anticoagulant used in the management of Non-ST-Elevation Myocardial Infarction (NSTEMI). It works by inhibiting factor Xa, which plays a crucial role in the coagulation process. By inhibiting this factor, fondaparinux helps reduce the formation of blood clots, thereby improving outcomes in patients with NSTEMI. This anticoagulant is specifically recommended for the treatment of NSTEMI due to its efficacy in preventing thrombus formation while minimizing the risk of bleeding complications. Its use is supported in clinical guidelines, particularly for patients who are at high risk for thrombosis. The other substances listed, while relevant to anticoagulation or blood thinning therapies, do not match the specific recommendation for NSTEMI management in the same manner that fondaparinux does. Warfarin, for example, is primarily used for long-term anticoagulation and is not typically indicated in acute NSTEMI settings. Rivaroxaban is a direct factor Xa inhibitor and is used for various conditions but is not the primary recommendation for NSTEMI. Enoxaparin, while commonly used in the management of NSTEMI, is not the correct answer as the focus of the